pharma news today glp-1 obesity drugs today Market Size to Hit USD 132.79 Bn by 2035 Pfizer moves forward with weight-loss
Description
Most GLP-1 and dual GIP/GLP-1 agonists are injected
It is the time to change the paradigms of pregnant and breastfeeding women in clinical research
10.2165/00003495-200868150-00005 103 KumarS.MittalA.MittalA
Structurally identical to native exendin-4, exenatide is a chemically synthesized peptide with clinical applications in the management of type 2 diabetes
Fiber undergoes bacterial fermentation in the colon, producing short-chain fatty acids (SCFAs)particularly butyrate, propionate, and acetatewhich can stimulate L-cell GLP-1 secretion
Medication-based treatments are emerging, with Zepbound being the first approved drug in this category
